Jiao XD - Search Results

1

HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.

Jiao XD, Liu K, Wu Y, Zhou XC, Qin BD, Ling Y, Liu J, He X, Du H, Xiang J, Zang YS. Jiao XD, et al. Oncologist. 2021 Sep;26(9):717-721. doi: 10.1002/onco.13799. Epub 2021 May 20. Oncologist. 2021. PMID: 33896090 Free PMC article.

2

Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report.

Jiao XD, Luo X, Qin WX, Yuan LY, Zang YS. Jiao XD, et al. Mol Clin Oncol. 2016 May;4(5):824-826. doi: 10.3892/mco.2016.782. Epub 2016 Feb 16. Mol Clin Oncol. 2016. PMID: 27123288 Free PMC article.

3

[Advances in Patient Derived Tumor Xenograft (PDTX) Model from Lung Cancer].

Qin B, Jiao X, Yuan L, Liu K, Zang Y. Qin B, et al. Zhongguo Fei Ai Za Zhi. 2017 Oct 20;20(10):715-719. doi: 10.3779/j.issn.1009-3419.2017.10.09. Zhongguo Fei Ai Za Zhi. 2017. PMID: 29061220 Free PMC article. Review. Chinese.

4

Increased SNAT1 is a marker of human osteosarcoma and potential therapeutic target.

Wang M, Liu Y, Fang W, Liu K, Jiao X, Wang Z, Wang J, Zang YS. Wang M, et al. Oncotarget. 2017 Sep 5;8(45):78930-78939. doi: 10.18632/oncotarget.20693. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108276 Free PMC article.

5

Primary pulmonary leiomyosarcoma: A population-based study.

Qin BD, Jiao XD, Zang YS. Qin BD, et al. Among authors: jiao xd. Lung Cancer. 2018 Feb;116:67-72. doi: 10.1016/j.lungcan.2017.12.015. Epub 2017 Dec 29. Lung Cancer. 2018. PMID: 29413053

6

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.

Jiao XD, Ding C, Zang YS, Yu G. Jiao XD, et al. BMC Cancer. 2018 Feb 20;18(1):206. doi: 10.1186/s12885-018-4116-0. BMC Cancer. 2018. PMID: 29463236 Free PMC article.

7

Adenosquamous carcinoma of the bile duct: a population-based study.

Qin BD, Jiao XD, Yuan LY, Liu K, Zang YS. Qin BD, et al. Among authors: jiao xd. Cancer Manag Res. 2018 Mar 7;10:439-446. doi: 10.2147/CMAR.S144850. eCollection 2018. Cancer Manag Res. 2018. PMID: 29563834 Free PMC article.

8

Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.

Qin BD, Jiao XD, Zang YS. Qin BD, et al. Among authors: jiao xd. Med Hypotheses. 2018 Jul;116:111-113. doi: 10.1016/j.mehy.2018.05.005. Epub 2018 May 16. Med Hypotheses. 2018. PMID: 29857892

9

The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.

Jiao XD, Qin BD, You P, Cai J, Zang YS. Jiao XD, et al. Lung Cancer. 2018 Sep;123:70-75. doi: 10.1016/j.lungcan.2018.07.003. Epub 2018 Jul 4. Lung Cancer. 2018. PMID: 30089598

10

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review.

Qin BD, Jiao XD, Yuan LY, Liu K, Wang Z, Qin WX, Zang YS. Qin BD, et al. Among authors: jiao xd. Onco Targets Ther. 2018 Aug 10;11:4739-4745. doi: 10.2147/OTT.S167346. eCollection 2018. Onco Targets Ther. 2018. PMID: 30127622 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters